Swiss subsidiary Rhizen Pharmaceuticals S.A. entered into an exclusive, worldwide license agreement with Novartis for the development and commercialization of Rhizen's, inhaled dual Pl3K-delta gamma inhibitor and its closely related compounds for various indications.
The stock opened higher at Rs. 680 as against its previous close of Rs. 668.60. It hit a high and a low of Rs. 688 and Rs. 670.40 respectively. So far, a total of 26,257 (BSE+NSE) shares have changed hands.
The scrip opened at Rs. 680 and has touched a high and low of Rs. 688 and Rs. 670 respectively. So far 27967(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 12603.11 crore.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 791.7 on 15-Jul-2015 and a 52 week low of Rs. 381.9 on 26-Feb-2015. Last one week high and low of the scrip stood at Rs. 702.4 and Rs. 666 respectively.
The promoters holding in the company stood at 74.13 % while Institutions and Non-Institutions held 12.6 % and 13.28 % respectively.
The stock is currently trading above its 100 DMA.
No comments:
Post a Comment